AngioDynamics, Inc. (NASDAQ:ANGO) Receives $19.33 Consensus PT from Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $19.3333.

ANGO has been the subject of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, January 21st. Zacks Research raised AngioDynamics from a “hold” rating to a “strong-buy” rating in a research note on Friday, January 9th. Finally, Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $10.97 on Friday. The company has a market capitalization of $452.18 million, a P/E ratio of -16.37 and a beta of 0.51. AngioDynamics has a 1-year low of $8.27 and a 1-year high of $13.99. The firm’s 50 day simple moving average is $11.63 and its two-hundred day simple moving average is $11.20.

Hedge Funds Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Franklin Resources Inc. grew its stake in AngioDynamics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after acquiring an additional 1,076 shares in the last quarter. Farther Finance Advisors LLC grew its position in shares of AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares in the last quarter. State of Wyoming grew its position in shares of AngioDynamics by 53.6% during the third quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 1,658 shares in the last quarter. Deutsche Bank AG lifted its position in shares of AngioDynamics by 5.9% in the fourth quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after buying an additional 1,992 shares in the last quarter. Finally, State of Alaska Department of Revenue purchased a new position in AngioDynamics during the 3rd quarter valued at approximately $25,000. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.